Aastrom Biosciences Inc., a developer of stem cell therapies, said Wednesday follow-up data on an early-to-midstage study indicated its tissue repair cells may help bone regeneration.
The 12-month follow-up showed that 18 of the 20 patients involved with severe long bone fractures had multiple bone bridges, which is a sign of bone regeneration. In all, 36 patients are involved in the follow-up, but only 20 have completed the 12-month period.
The patients all had fractures in either their tibia, femur or humerus bones which failed to heal with standard bone grafting and surgical treatments.
Shares of Aastrom rose 5 cents, or 3.5 percent, to $1.49 in morning trading on the Nasdaq.
The 12-month follow-up showed that 18 of the 20 patients involved with severe long bone fractures had multiple bone bridges, which is a sign of bone regeneration. In all, 36 patients are involved in the follow-up, but only 20 have completed the 12-month period.
The patients all had fractures in either their tibia, femur or humerus bones which failed to heal with standard bone grafting and surgical treatments.
Shares of Aastrom rose 5 cents, or 3.5 percent, to $1.49 in morning trading on the Nasdaq.
posted by doublezero at
9:12 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home